Catalyst Pharmaceuticals, Inc.
CPRX Mid CapHealthcare · Biotechnology
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sab
Catalyst Pharmaceuticals, Inc. Stock at a Glance
Catalyst Pharmaceuticals, Inc. (CPRX) is currently trading at $31.36 with a market capitalization of $3.8B. The trailing P/E ratio stands at 18.13x, with a forward P/E of 9.86x. The 52-week range spans from $19.05 to $32.56; the current price is 3.7% below the yearly high. Year-over-year revenue growth stands at +5.6%. The net profit margin stands at 37.08%.
💰 Dividend
Catalyst Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
3 analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) on consensus: Hold. The average price target is $31.67, implying +0.98% from the current price. Analyst price targets range from $31.50 to $32.00.
Catalyst Pharmaceuticals, Inc.: The Investment Case in Detail
Catalyst Pharmaceuticals, Inc. (CPRX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 84.04%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 37.08%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
What to Watch Next
- The forward P/E of 9.86x is meaningfully below the trailing 18.13x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 91.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Profitable with 37.08% net margin
- High return on equity (24.5% ROE)
- High gross margin of 84.04% — indicates pricing power
- Solid balance sheet with low debt (D/E 0.27)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (8.29%).
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Catalyst Pharmaceuticals, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news